B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure  by de Groote, Pascal et al.
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-Type Natriuretic Peptide and
eak Exercise Oxygen Consumption Provide
ndependent Information for Risk Stratification
n Patients With Stable Congestive Heart Failure
ascal de Groote, MD,* Joe¨l Dagorn, MD,* Benoit Soudan, MD,† Nicolas Lamblin, MD,*
ugene McFadden, FRCPI, FACC,‡ Christophe Bauters, MD, FACC*
ille, France; and Rotterdam, The Netherlands
OBJECTIVES The aim of this study was to compare the prognostic value of peak oxygen consumption (VO2)
and B-type natriuretic peptide (BNP) in patients with stable congestive heart failure (CHF).
BACKGROUND Previous studies have demonstrated that both peak VO2 and BNP are useful for risk
stratification in patients with CHF. No study has compared the respective prognostic value
of these two parameters in a large series of patients receiving a combination of angiotensin-
converting enzyme inhibitors and of beta-blockers.
METHODS Patients with stable CHF underwent radionuclide angiography, echocardiography, 24-h
Holter monitoring, and a cardiopulmonary exercise test. Blood samples were drawn for
standard measurements and for hormonal determinations.
RESULTS After a median follow-up period of 787 days, there were 75 cardiac-related deaths and three
urgent transplantations. Independent predictors of cardiac survival were percent of maximal
predicted VO2 (%VO2, relative risk [RR] 2.84 [95% confidence interval, CI 1.73 to 4.65],
p  0.00001), BNP (RR  3.17 [95% CI 1.68 to 5.96], p  0.0004), left atrial diameter
(LAD) (RR  2.04 [95% CI 1.25 to 3.34], p  0.004), age (RR  1.93 [95% CI 1.22 to
3.05], p 0.005), and aldosterone (RR 1.84 [95% CI 1.12 to 3.00], p 0.015). In patients
with infra-median levels of BNP (109 pg/ml), age was the only independent predictor of
cardiac survival. However, in patients with supra-median levels of BNP, independent
predictors of cardiac survival were %VO2 (RR  3.76 [95% CI 2.19 to 6.45], p  0.00001)
and LAD (RR  1.90 [95% CI 1.10 to 3.28], p  0.02).
CONCLUSIONS B-type natriuretic peptide, in combination with %VO2, improves risk stratification of patients
with stable CHF. (J Am Coll Cardiol 2004;43:1584–9) © 2004 by the American College
of Cardiology Foundationu
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Bisk stratification is an integral part of management in
atients with congestive heart failure (CHF) and is an
mportant step before defining the optimal treatment strat-
gy, particularly given the limited availability of some
herapies such as cardiac transplantation. Previous studies
ave demonstrated that variables such as New York Heart
ssociation (NYHA) classification , left ventricular ejection
raction (LVEF), or peak oxygen consumption (VO2) were
owerful, independent predictors of survival in CHF pa-
ients (1,2). In recent years, exercise testing has become an
ncreasingly important tool in the selection of patients for
eart transplantation. It has been shown that ambulatory
HF patients who can achieve a peak VO2 14 ml/kg/min
r a percent maximal predicted VO2 (%VO2) 50% are at
ow risk of cardiac mortality, and thus cardiac transplanta-
ion can safely be deferred (2,3). Other studies have focused
n hormonal activation and in particular on B-type natri-
From the *Service de Cardiologie C, Hoˆpital Cardiologique, †Laboratoire
’endocrinologie, Clinique Linquette, CHRU, 59037 Lille Cedex, France, and
Thoraxcenter, Erasmus Medical Centre, Rotterdam, The Netherlands. Dr. Carl V.
eier acted as Guest Editor.wManuscript received October 13, 2003; accepted November 12, 2003.retic peptide (BNP). Several studies have demonstrated
hat BNP was an independent predictor of cardiac survival
4–6). Because there is a correlation between BNP and
xercise capacity, it has been suggested that BNP assay
ight be an easy alternative to peak VO2 for the selection of
igh-risk patients (7). However, to the best of our knowl-
dge, no study has compared the prognostic value of peak
O2 or BNP in a population of patients with a modern
reatment of CHF, that includes both angiotensin-
onverting enzyme inhibitors (ACE-I) and beta-blockers.
Accordingly, we designed the present study in 407
onsecutive CHF patient who underwent a prognostic
valuation in our institution and who had systematic deter-
ination of a large set of prognostic variables, including
eak VO2 and BNP.
ETHODS
rotocol. All patients referred to our department for a
on-invasive evaluation of left ventricular systolic dysfunc-
ion were prospectively considered for inclusion in the study.
efore inclusion, treatment of the patients was optimized
ith introduction and/or up-titration to maximal tolerated
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May 5, 2004:1584–9 BNP and VO2 in CHFoses of ACE-I and/or beta-blockers. Patients with recent
ntroduction of beta-blockers were included three months
fter maximal tolerated doses were reached. During optimi-
ation of the treatment, patients had systematic coronary
ngiography to help define the etiology of left ventricular
ystolic dysfunction. Patients were included after optimiza-
ion of their treatment if they were ambulatory, stable for at
east two months, and had a LVEF  45%. Patients were
xcluded if they had a myocardial infarction, an episode of
nstable angina, or had undergone coronary revasculariza-
ion in the previous three months.
All the patients included in this analysis underwent
chocardiography, radionuclide angiography, 24-h Holter
onitoring, and a cardiopulmonary exercise test as previ-
usly described (8). Blood samples were drawn in the
orning in the supine position for standard measurements
nd hormonal determinations. For hormonal determina-
ion, samples were immediately put on ice, centrifuged at
°C within 20 min, and the supernatant was immediately
tored at 70°C until assayed. Plasma BNP concentrations
ere measured by radioimmunoassay (Shionoria BNP kit;
hionogi & Co. Ltd., Osaka, Japan). Normal values were
21.1 pg/ml with inter-assay and intra-assay coefficients of
ariation of 4.2% and 2.7%, respectively, for the concentra-
ion of 21.1 pg/ml and 2.1% and 2%, respectively, for the
oncentration of 520 pg/ml. Plasma endothelin-1 concen-
rations were measured by radioimmunoassay (Nichols In-
titute Diagnostics BV, San Clemente, California) after
xtraction on a Sep-Pak C-18 cartridge. The normal range
f endothelin-1 was 1.1 to 2.3 pmol/l with inter-assay and
ntra-assay coefficients of variation of 6.8% and 4.5%,
espectively. Plasma aldosterone concentrations were mea-
ured by radioimmunoassay (Beckman Coulter Immuno-
ech, Villepinte, France). The normal range was 10 to 160
g/ml with inter-assay and intra-assay coefficients of varia-
ion below 9.9% and 9.5%, respectively. Plasma levels of
orepinephrine were determined by high-performance liq-
id chromatography. The normal range was 100 to 600
g/ml with inter-assay and intra-assay coefficients of varia-
ion of 5.2% and 7.5%, respectively.
efinitions. Ischemic cardiomyopathy was defined as pa-
ients with a proven history of myocardial infarction (sig-
Abbreviations and Acronyms
ACE-I  angiotensin-converting enzyme inhibitors
BNP  B-type natriuretic peptide
CHF  congestive heart failure
CI  confidence interval
LAD  left atrial diameter
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
RR  relative risk
UNOS  United Network for Organ Sharing
VO2  peak oxygen consumption
%VO2  percent maximal predicted VO2ificant Q waves on the electrocardiogram and/or signifi- mant increase in creatinine kinase levels during a previous
ospitalization) and/or stenosis 50% in one of the major
oronary arteries. Patients who did not fulfill these criteria
ere considered to have a non-ischemic cardiomyopathy. If
oronary angiography was not performed or if the patient
id not have a proven history of myocardial infarction,
atients were considered to have undetermined cardiomy-
pathy, except for young patients (30 years old) without
ny risk factor for atherosclerosis. These patients were
onsidered to have non-ischemic cardiomyopathy. Patients
ere classified as diabetic if they were treated by oral
ypoglycemic drugs or insulin or if they had a previous
istory, documented on their medical chart, of elevated (126
g/dl) fasting blood glucose on at least two separate
ccasions in conjunction with adhering to ongoing dietary
easures to control their glucose level. The qualitative
lassification of doses of ACE-I was defined using the
ecommendations of the European Society of Cardiology
9). High doses were defined as the highest recommended
oses, intermediate doses as the lowest recommended doses,
nd low doses as the non-recommended doses of ACE-I.
estrictive mitral inflow patterns were defined as a ratio of
arly transmitral flow velocity to atrial flow velocity (E/A
atio) 2 or an E/A ratio between 1 and 2 with a mitral
eceleration time 140 ms (10,11). In patients with atrial
brillation, restrictive mitral inflow pattern was defined as a
itral deceleration time 140 ms (12). Severe ventricular
rrhythmias were defined by the number of single ventric-
lar ectopic beats and the number of non-sustained ventric-
lar tachycardia (3 consecutive ventricular ectopic beats at
rate of 100/min).
atients. From March 1998 to December 2001, 424 am-
ulatory patients were referred to our department for
on-invasive evaluation of left ventricular systolic dysfunc-
ion with a LVEF  45%. Of these patients, 17 (4%) were
ot included because of technical reasons involving either
adionuclide angiography (n 7), cardiopulmonary exercise
est (n  4), or hormonal determinations (n  6). During
he follow-up period of these 17 patients, there were four
ardiovascular deaths and two non-cardiac deaths.
tatistics. Results are expressed as mean  SD except for
ormonal values and ventricular ectopic beats presented as
edian with 95% confidence intervals (CI). Discrete vari-
bles were compared using chi-square analysis. Continuous
ariables were compared by unpaired Student t test or by the
on-parametric Mann-Whitney test. Follow-up was per-
ormed either by direct examination or by contact with the
eneral practitioner. Cardiac mortality was defined as
ardiac-related death or urgent cardiac transplantation
United Network for Organ Sharing [UNOS] status 1) (13),
nd patients who had non-urgent transplantation (UNOS
tatus 2) (13) were censored at the time of transplantation.
ardiac event was defined as cardiac-related death or
ardiac transplantation (UNOS status 1 and 2). The
aplan-Meier method was performed to estimate the cu-
ulative survival. Differences in survival were compared
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BNP and VO2 in CHF May 5, 2004:1584–9ith a log-rank test. Cutoff values were determined by
eceiver operating characteristic curves analysis. Several
ultivariate Cox proportional hazard analyses were per-
ormed to determine the independent predictors of cardiac
urvival and of cardiac events free survival for the entire
opulation and in subgroups of patients. Variables signifi-
ant in univariate analysis at a p level of 0.1 were entered in
ur Cox analysis. Independent relative risks (RR) are
resented with 95% CI. A value of p  0.05 was considered
tatistically significant. Statistics were performed with SPSS
oftware version 9 (SPSS, Chicago, Illinois).
ESULTS
linical characteristics of the study population are summa-
ized in Table 1. Of the 407 patients included in the study,
refused coronary angiography and were classified as having
n undetermined etiology. Most of the patients were receiv-
ng ACE-I (95%), of whom 16 patients were receiving low
oses, 54 moderate doses, and 315 high doses; 5% of the
atients were receiving angiotensin II type I receptor block-
rs; 93% were receiving beta-blockers (bisoprolol: n  220,
ean dose: 8.5  2.7 mg by day; carvedilol: n  98, 52 
8 mg by day; others beta-blockers: n  61), 81% diuretics,
6% spironolactone, and 40% digoxin.
Table 1. Major Characteristics of the Entire P
Entire Po
n 407
Age, yrs 57 
NYHA class III, n (%) 107 (2
Atrial fibrillation, n (%) 52 (1
Diabetes mellitus, n (%) 114 (2
History of hypertension, n (%) 167 (4
Ischemic cardiomyopathy, n (%) 184 (4
Heart rate at rest, beats/min 80 
Systolic blood pressure at rest, mm Hg 117 
QRS duration, ms 119 
Complete LBBB, % 88 (2
Left ventricular ejection fraction, % 33 
Right ventricular ejection fraction, % 39 
Peak VO2, ml/min/kg 15.2 
%VO2 59.4 
LAD, mm 44.2 
LVEDD, mm 64.8 
E/A ratio 1.48 
Mitral deceleration time, ms 175 
Mitral restictive flow, n (%) 166 (4
Ventricular ectopic beats, n/24 h 296 [0–1
Ventricular ectopic beats 30/h, n (%) 139 (3
Non-sustained VT, n (%) 55 (1
Sodium, mEq/l 138 
Creatinine, mg/l 11.4 
Norepinephrine, mg/l 370 [140
BNP, pg/ml 110 [7–9
Aldosterone, pg/ml 56 [14.7
Endothelin-1, pmol/l 1.73 [0.5–
Hormonal values and ventricular ectopic beats are presented
BNP  B-type natriuretic peptide; E/A  ratio of early
diameter; LBBB  left bundle-branch block; LVEDD  le
Association; %VO2  percent of maximal predicted oxygenDuring a median follow-up period of 787 days, there cere 75 cardiac-related deaths, 3 UNOS status 1 transplan-
ations, 13 UNOS status 2 transplantations, and 11 non-
ardiovascular deaths. No patient was lost to follow-up.
ifferences in clinical characteristics between survivors and
on-survivors are presented in Table 1. Mortality rates at
ne and two years were 11% and 16%, respectively.
Independent predictors of cardiac survival and of cardiac
vent free survival are summarized in Table 2. Most
owerful predictors were %VO2, BNP, and left atrial diam-
ter (LAD). If %VO2 is not included in the multivariate
nalysis, NYHA classification (RR  1.63 [95% CI 1.02 to
.63], p  0.04) is selected as an independent predictor of
ardiac survival. Similarly, if both %VO2 and BNP are not
ncluded in the analysis, NYHA classification (RR  2.04
95% CI 1.28 to 3.25], p  0.003) and LVEF (RR  1.76
95% CI 1.08 to 2.87], p  0.02) are selected in the final
odel. All results were similar if we excluded from the
nalysis patients in atrial fibrillation.
ubgroup analyses. Peak VO2 is a helpful prognostic pa-
ameter for risk stratification of CHF patients. We thus
erformed analyses to determine if BNP remained an
ndependent predictor of cardiac survival in subgroups of
atients divided according to peak VO2 (Table 3). In all the
nalyses, BNP was selected as an independent predictor of
tion and of Survivors and of Non-Survivors
on Survivors Non-Survivors p Value
329 78
56  11 61  11 0.0002
72 (22%) 35 (45%)  0.0001
35 (11%) 17 (22%) 0.008
87 (26%) 27 (35%) NS
136 (41%) 31 (40%) NS
135 (41%) 49 (63%) 0.0008
79  18 84  18 NS
117  20 117  21 NS
117  31 130  44 0.03
69 (21%) 19 (24%) NS
35  12 26  12  0.0001
40  12 35  13 0.002
15.9  4.7 12.3  4.1  0.0001
62.1  16.9 47.7  14.2  0.0001
42.8  7.9 49.8  8.9  0.0001
63.8  9.6 69.1  11.1  0.0001
1.38  1.11 1.89  1.24 0.002
181  78 146  78 0.0007
118 (36%) 48 (62%)  0.0001
] 270 [0–8,281] 600 [4–14,179] 0.002
104 (32%) 35 (45%) 0.02
41 (12%) 14 (18%) NS
138  3.2 137  4.2 0.003
11.1  3.2 12.8  3.7  0.0001
340 [140–860] 570 [190–1,450]  0.0001
84 [6–818] 400 [38–1,573]  0.0001
] 54 [14–252] 77 [15–576]  0.0001
1.6 [0.5–4.1] 2.2 [0.7–6.2]  0.0001
dian with [95% confidence interval].
itral flow velocity to atrial flow velocity; LAD  left atrial
tricular end-diastolic diameter; NYHA  New York Heart
ption; VT  ventricular tachycardia.opula
pulati
11
6%)
3%)
8%)
1%)
5%)
18
20
34
2%)
13
12
4.8
7.4
8.6
10.1
1.15
79
1%)
0,300
4%)
4%)
3.5
3.3
–970]
57]
–326
4.5]
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May 5, 2004:1584–9 BNP and VO2 in CHFWe then analyzed whether determination of plasma BNP
ay help to identify patients who need more extensive risk
tratification. Table 4 shows independent predictors of
ardiac survival in subgroups of patients divided according
o plasma BNP levels. In the subgroup of patients with
nfra-median levels of BNP (109 pg/ml), the only inde-
endent predictor of cardiac survival was age; other variables
ere not useful for risk stratification in this subgroup with
very low cardiac mortality (2% at 1 year, 3% at 2 years). By
ontrast, in the subgroup of patients with plasma BNP
109 pg/ml, %VO2 and LAD were strong independent
redictors of cardiac survival; when BNP was entered into
he model as a quantitative variable or as a qualitative
ariable, it was not an independent predictor of cardiac
urvival in this subgroup.
Figure 1 shows the survival curves of subgroups divided
ccording to %VO2 and BNP. Patients with BNP109 pg/ml
nd %VO250% had the worse prognosis with a mortality rate
t 1 and 2 years of 30% and 45%, respectively. In patients with
able 2. Results of the Multivariate Analyses: Independent
redictors of Cardiac Survival and of Cardiac Event–Free
urvival
Wald
Chi-Square RR [95% CI] p Value
ardiac survival
%VO2 17.2 2.84 [1.73–4.65]  0.00001
BNP 12.7 3.17 [1.68–5.96] 0.0004
LAD 8.1 2.04 [1.25–3.34] 0.004
Age 8 1.93 [1.22–3.05] 0.005
Aldosterone 5.9 1.84 [1.12–3.00] 0.015
ardiac event–free
survival
%VO2 20.4 2.99 [1.86–4.82]  0.00001
BNP 16.1 3.45 [1.88–6.31] 0.0001
LAD 9.47 2.10 [1.31–3.36] 0.002
Aldosterone 4.47 1.65 [1.04–2.62] 0.03
Creatinine 4.25 1.59 [1.02–2.47] 0.04
utoff values for %VO2, BNP, LAD, age, aldosterone, and creatinine were 50%, 109
g/ml, 45 mm, 65 years old, 56 pg/ml, and 12 mg/l, respectively.
CI  confidence interval; RR  relative risk. Other abbreviations as in Table 1.
Table 3. Independent Predictors of Cardiac Su
According to Peak VO2
Patients with a peak VO2  14 ml/min/kg
BNP
Creatinine
LAD
Patients with a peak VO2  14 ml/min/kg
BNP
Aldosterone
Creatinine
Patients with a % peak VO2  50%
LAD
BNP
Patients with a % peak VO2  50%
Creatinine
BNPCI  confidence interval; RR  relative risk. Other abbreviationsNP 109 pg/ml and %VO2 50%, mortality rates were 9%
nd 13%, respectively (independent RR between these two
ubgroups was 3.14 [95% CI 1.8 to 5.5], p  0.0001). In
atients with plasma levels of BNP109 pg/ml, there was no
ignificant difference in subgroups divided according to %VO2.
owever, there was a significant difference between patients
ith BNP  109 pg/ml and patients with BNP 109 pg/ml
nd %VO250% (RR 2.32 [95% CI 1.1 to 4.8], p 0.03).
ISCUSSION
n recent years, several studies have demonstrated the
nterest of BNP determination for the management of CHF
atients. B-type natriuretic peptide is associated with car-
iac survival (4–6), and is also a helpful parameter for the
iagnosis of CHF and for the therapeutic monitoring of
HF patients (14,15). Kru¨ger et al. (7) found a correlation
etween BNP and VO2, suggesting that BNP could be an
lternative to VO2 for risk stratification. Similarly, Koglin et
l. (16) demonstrated that BNP was as useful as the heart
ailure survival score, validated by Aaronson et al. (17), to
redict survival. The emerging concept for the management
f CHF patients is to determine the plasma levels of BNP
or risk stratification because it is easier, more cost-effective,
nd less time-consuming than other sophisticated tech-
iques, such as cardiopulmonary exercise testing.
The present study highlights the importance of combining
l in Subgroups of Patients Divided
ald
Square RR [95% CI] p Value
.71 5.24 [1.85–14.9] 0.002
.89 1.99 [1.85–3.47] 0.015
.37 1.97 [1.04–3.74] 0.04
.08 3.52 [1.55–7.99] 0.003
.44 2.32 [1.06–5.09] 0.035
.27 2.38 [1.05–5.43] 0.04
.13 2.66 [1.23–5.76] 0.013
12 [1.64–87.6] 0.014
.06 2.95 [1.40–6.23] 0.0045
.81 2.54 [1.19–5.41] 0.016
able 4. Independent Predictors of Cardiac Survival in
ubgroups of Patients Divided According to Plasma BNP
Wald
Chi-Square RR [95% CI] p Value
atients with a plasma BNP
 109 pg/ml
Age 11.1 6.67 [2.18–20.4] 0.0009
atients with a plasma BNP
 109 pg/ml
%VO2 23.2 3.76 [2.19–6.45]  0.00001
LAD 5.32 1.90 [1.10–3.28] 0.02
bbreviations as in Table 1.rviva
W
Chi-
9
5
4
9
4
4
6
6
8
5as in Table 1.
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BNP and VO2 in CHF May 5, 2004:1584–9NP and %VO2 for an optimal risk stratification in CHF
atients. We demonstrated that these two parameters give
ndependent prognostic information. The highest mortality
ate was observed in patients who had both BNP109 pg/ml
nd %VO2 50%; they had an almost threefold increase in
ardiovascular mortality at two years compared with patients
ith BNP 109 pg/ml and %VO2 50%. Moreover, the risk
f dying from a cardiovascular cause was double in patients
ith BNP 109 pg/ml and %VO2 50% compared with
atients with BNP 109 pg/ml. Patients with BNP 109
g/ml have an excellent prognosis: in this low-risk subgroup,
he only independent predictor of cardiac survival is age, and
hus a more sophisticated prognostic evaluation is not required.
n contrast, patients with BNP 109 pg/ml benefit from a
ubsequent prognostic evaluation, including cardiopulmonary
xercise testing and echocardiography. In this subgroup, BNP
s not useful for risk stratification and %VO2 and LAD are the
ndependent predictors of cardiac survival.
A strength of this study is related to the determination
f a number of well-known prognostic parameters, such
s serum sodium, serum creatinine, norepinephrine,
ndothelin-1, or mitral deceleration time (1,11,18,19). In
ur population, LAD is a more powerful prognostic param-
ter than the restrictive mitral pattern. Previous studies have
igure 1. Kaplan-Meier survival curves in subgroups of patients divided acc
f percentage of maximal predicted VO2 (%VO2).emonstrated that left atrial enlargement (defined using wither area or volume) was an independent predictor of
ardiac events in patients with CHF (11,12,20,21) but also
n the general population (22).
tudy limitations. Our conclusions cannot be extended to
ll CHF patients. We studied ambulatory patients after
ptimization of their treatment, including maximal toler-
ted doses of both ACE-I and beta-blockers. Hemody-
amic parameters were not included in our multivariate
nalyses because we performed a non-invasive evaluation in
mbulatory CHF patients. Hemodynamic parameters may
e useful to refine risk stratification, especially in a subgroup
f patients with both BNP 109 pg/ml and %VO2 50%
18). Similarly, new echocardiographic parameters analyz-
ng left ventricular diastolic function and information re-
arding heart rate variability were not available for all the
atients. Previous studies have demonstrated the usefulness
f such parameters in risk stratification (23–25).
In conclusion, BNP determination and peak VO2 provide
ndependent information for risk stratification in patients with
table CHF. The results of the present study suggest that a
wo-step prognostic evaluation could be performed in CHF
atients, with initial determination of plasma BNP in all
atients and a subsequent, more complete prognostic evalua-
ion, including a cardiopulmonary exercise test, for patients
g to cutoff values of plasma levels of B-type natriuretic peptide (BNP) andordinith BNP 109 pg/ml.
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